ValiRX CEO Dr Mark Eccleston joined Steve Darling from Proactive to discuss the company’s progress across its expanding oncology and animal health pipeline as the company advances multiple therapeutic assets through its special purpose vehicle (SPV) strategy.
Eccleston said the AIM-listed biotechnology company continued to focus on identifying, evaluating and de-risking promising therapeutic assets before advancing them within dedicated commercial entities.
Eccleston said the structure allowed each programme to operate with a specialised management focus while leveraging shared expertise across the wider ValiRx group. He added that the model also enabled individual assets to become independently investable, helping reduce dilution pressure on existing shareholders.
A key development discussed during the interview was ValiRx’s evaluation of a new oncology asset licensed under evaluation from McGill University. Eccleston described the programme as “probably the best asset that we’ve ever had in house to evaluate.”
The asset is initially being assessed for osteosarcoma, a bone cancer affecting both humans and dogs. Eccleston noted that osteosarcoma in canines closely mirrors the disease in humans, creating an opportunity to utilise comparative oncology approaches that could accelerate clinical data generation.
He explained that canine osteosarcoma prevalence is substantially higher than in humans, allowing broader access to real-world clinical data while simultaneously supporting therapeutic development for companion animals and human patients.
ValiRx also continues advancing several oncology-focused programmes targeting areas of significant unmet medical need. Its Cytolytix oncolytic peptide programme is focused on triple negative breast cancer, while the VAL201 programme, now housed within Blue Ribbon Bio, is being developed primarily for prostate cancer alongside additional applications in breast cancer and endometriosis.
Eccleston stated that many of the company’s therapeutic assets possess “multi cancer potential,” allowing multiple indications to be pursued using shared mechanisms and development pathways.
Looking ahead, the company expects several potential catalysts over the coming months. These include decisions regarding new in-licensing opportunities, patent developments linked to Cytolytix assets, and outcomes from multiple grant funding applications.
Eccleston said ValiRx was awaiting results from several major funding applications between July and year-end, including six-figure and seven-figure grant opportunities. He suggested that successful outcomes from these programmes, including European funding initiatives, could prove transformational for the company’s future development plans.
#proactiveinvestors #valirxplc #aim #val #CancerResearch #TripleNegativeBreastCancer #OncologyInnovation #Cytolytix #PharmaPipeline #WomensHealth #PrecisionMedicine #Biotech #ArtificialIntelligence #DrugDevelopment #Oncology #MedicalResearch #CompanionAnimalHealth #CancerResearch #HealthcareInnovation
